$MRK Company News Dow industrials suffer worst d
Post# of 102453
Posted On: 01/25/2014 10:15:44 AM
$MRK Company News
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Beam up on Suntory deal; Elliott report lifts Juniper 4:17 p.m. Jan. 13, 2014 - Saumya Vaishampayan
Merck shares hit 52-week high on drug hopes, plans for cutbacks 12:31 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Merck initiates melanoma filing with FDA 11:45 a.m. Jan. 13, 2014 - Tess Stynes
Merck shares rise 3%, best on Dow average 9:41 a.m. Jan. 13, 2014 - Laura Mandaro
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - blogs.marketwatch.com
Cholesterol drugs: Do you need them, or not? 5:00 a.m. Jan. 8, 2014 - Elizabeth O'Brien
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Merck, Twitter, Apple are stocks to watch 4:34 p.m. Dec. 29, 2013 - Wallace Witkowski
Merck to revamp its R&D practices: WSJ 4:49 p.m. Dec. 27, 2013 - Wallace Witkowski
Merck to radically reshape R&D unit: WSJ 4:40 p.m. Dec. 27, 2013 - Wallace Witkowski
Not all pharmaceuticals are created equal 12:39 p.m. Dec. 26, 2013 - The Trading Deck
EU approves Merck's Erbitux for cancer treatment 4:52 a.m. Dec. 23, 2013 - MarketWatch.com
Biotechs continue to pay off 10:27 a.m. Dec. 20, 2013 - The Trading Deck
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Merck, McDonald's are top decliners in Dow index 4:05 p.m. Dec. 4, 2013 - Polya Lesova
Cuts, stock buyback, acquisition combine to boost Forest shares 11:09 a.m. Dec. 2, 2013 - blogs.marketwatch.com
Merck, J.P. Morgan lead Dow decliners 9:35 a.m. Nov. 13, 2013 - Laura Mandaro
Merck, Cisco lead gainers in Dow industrials 4:03 p.m. Nov. 12, 2013 - Polya Lesova
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Five Big Stocks That Escaped The Market Carnage Sell-Off 7:28 a.m. Today - 247WallSt.com
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Today - Barrons.com
Focus On Cancer Immunotherapy Results 3:41 a.m. Today - Seeking Alpha
Big Pharmas Battle For The Billion-Dollar Melanoma Market 6:42 p.m. Jan. 24, 2014 - Seeking Alpha
Dow Today: Merck (MRK) Leads The Day Higher, Visa (V) Lags 4:30 p.m. Jan. 24, 2014 - TheStreet.com
Amgen Reports Positive Evolocumab Data - Analyst Blog 4:30 p.m. Jan. 24, 2014 - Zacks.com
Do Patent Expirations Mean Fewer Jobs At Novartis? 10:26 a.m. Jan. 24, 2014 - Wall St. Cheat Sheet
Turbocharged Dividends 8:05 a.m. Jan. 24, 2014 - Barrons.com
Cramer's Mad Money - It's All About Icahn (1/23/14) 5:56 a.m. Jan. 24, 2014 - Seeking Alpha
The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly 11:26 a.m. Jan. 23, 2014 - TheStreet.com
Bristol-Myers' New Nivolumab Trial Sparks Worries 10:15 a.m. Jan. 23, 2014 - Investors Business Daily
Drugmaker Merck Tries To Jump-Start Slow Growth 4:50 p.m. Jan. 22, 2014 - Investors Business Daily
5 Stocks That Dominated The Market Wednesday 3:34 p.m. Jan. 22, 2014 - 247WallSt.com
Johnson & Johnson Balances Earnings Beat With Modest Guidance 9:23 a.m. Jan. 21, 2014 - Wall St. Cheat Sheet
Buy Recommendation Reiterated For Merck & Co Inc 9:05 a.m. Jan. 21, 2014 - TheStreet.com
How Big Are Emerging Markets? 8:32 a.m. Jan. 21, 2014 - GuruFocus.com
Will 'Dogs of the Dow' ETF Continue to Shine in 2014? - ETF News And Commentary 7:45 a.m. Jan. 21, 2014 - Zacks.com
J&J Needs to Earn Investor Loyalty 1:30 p.m. Jan. 20, 2014 - WSJ.com
GCVRZ: Betting On The Sales Of Lemtrada In A Moving MS Drug Market 2:05 p.m. Jan. 19, 2014 - Seeking Alpha
Forest Laboratories - Aptalis Deal Sparks More Enthusiasm 4:20 a.m. Jan. 19, 2014 - Seeking Alpha
RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics 10:06 a.m. Jan. 24, 2014 - ACCESSWIRE
ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet 8:05 a.m. Jan. 24, 2014 - GlobeNewswire
Formex CSO Blair West to Speak at 3rd Drug Formulation & Bioavailability Conference 10:00 a.m. Jan. 23, 2014 - PR Newswire - PRF
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
John Daly, Previous Merck Exec., Offers Consulting Tips 6:35 p.m. Jan. 17, 2014 - Marketwire
Sanford Heisler Adds Four New Class Representatives To $250M Gender Discrimination Class Action Suit Against Pharma Giant Merck 10:03 a.m. Jan. 17, 2014 - PR Newswire - PRF
Trimel Announces Appointment of Tom Rossi to Its Board of Directors 5:08 p.m. Jan. 16, 2014 - Marketwire
Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine 6:59 p.m. Jan. 15, 2014 - BusinessWire - BZX
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference 8:35 a.m. Jan. 13, 2014 - BusinessWire - BZX
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck 9:00 p.m. Jan. 12, 2014 - BusinessWire - BZX
Biotech Investing Strategies in 2014 Is Key Topic Bringing Investors to San Francisco for Biotech Showcase(TM) 2014 Next Week, January 13 10:59 a.m. Jan. 9, 2014 - BusinessWire
Dako to collaborate with Merck on development of companion diagnostics for cancer treatment 9:16 a.m. Jan. 9, 2014 - GlobeNewswire
Dako to collaborate with Merck on development of companion diagnostics for cancer treatment 9:00 a.m. Jan. 9, 2014 - Thomson Reuters ONE
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension 8:29 a.m. Jan. 8, 2014 - BusinessWire
Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix 8:00 a.m. Jan. 8, 2014 - PR Newswire
Forma Therapeutics Appoints Christopher Dinsmore to Vice President, Medicinal and Computational Chemistry 8:00 a.m. Jan. 7, 2014 - BusinessWire
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
Merck to Hold Fourth-Quarter 2013 Sales and Earnings Conference Call on February 5 4:59 p.m. Jan. 6, 2014 - BusinessWire
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma 7:00 a.m. Dec. 30, 2013 - Marketwire
Dow industrials suffer worst drop since Sept. 20: Stock market live blog recap 4:41 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Beam up on Suntory deal; Elliott report lifts Juniper 4:17 p.m. Jan. 13, 2014 - Saumya Vaishampayan
Merck shares hit 52-week high on drug hopes, plans for cutbacks 12:31 p.m. Jan. 13, 2014 - blogs.marketwatch.com
Merck initiates melanoma filing with FDA 11:45 a.m. Jan. 13, 2014 - Tess Stynes
Merck shares rise 3%, best on Dow average 9:41 a.m. Jan. 13, 2014 - Laura Mandaro
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - blogs.marketwatch.com
Cholesterol drugs: Do you need them, or not? 5:00 a.m. Jan. 8, 2014 - Elizabeth O'Brien
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Merck, Twitter, Apple are stocks to watch 4:34 p.m. Dec. 29, 2013 - Wallace Witkowski
Merck to revamp its R&D practices: WSJ 4:49 p.m. Dec. 27, 2013 - Wallace Witkowski
Merck to radically reshape R&D unit: WSJ 4:40 p.m. Dec. 27, 2013 - Wallace Witkowski
Not all pharmaceuticals are created equal 12:39 p.m. Dec. 26, 2013 - The Trading Deck
EU approves Merck's Erbitux for cancer treatment 4:52 a.m. Dec. 23, 2013 - MarketWatch.com
Biotechs continue to pay off 10:27 a.m. Dec. 20, 2013 - The Trading Deck
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Merck, McDonald's are top decliners in Dow index 4:05 p.m. Dec. 4, 2013 - Polya Lesova
Cuts, stock buyback, acquisition combine to boost Forest shares 11:09 a.m. Dec. 2, 2013 - blogs.marketwatch.com
Merck, J.P. Morgan lead Dow decliners 9:35 a.m. Nov. 13, 2013 - Laura Mandaro
Merck, Cisco lead gainers in Dow industrials 4:03 p.m. Nov. 12, 2013 - Polya Lesova
Bitcoin buying for dummies 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Five Big Stocks That Escaped The Market Carnage Sell-Off 7:28 a.m. Today - 247WallSt.com
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Today - Barrons.com
Focus On Cancer Immunotherapy Results 3:41 a.m. Today - Seeking Alpha
Big Pharmas Battle For The Billion-Dollar Melanoma Market 6:42 p.m. Jan. 24, 2014 - Seeking Alpha
Dow Today: Merck (MRK) Leads The Day Higher, Visa (V) Lags 4:30 p.m. Jan. 24, 2014 - TheStreet.com
Amgen Reports Positive Evolocumab Data - Analyst Blog 4:30 p.m. Jan. 24, 2014 - Zacks.com
Do Patent Expirations Mean Fewer Jobs At Novartis? 10:26 a.m. Jan. 24, 2014 - Wall St. Cheat Sheet
Turbocharged Dividends 8:05 a.m. Jan. 24, 2014 - Barrons.com
Cramer's Mad Money - It's All About Icahn (1/23/14) 5:56 a.m. Jan. 24, 2014 - Seeking Alpha
The Obsolescence of Provectus' Skin Cancer Drug Means Current Speculative Run Ends Badly 11:26 a.m. Jan. 23, 2014 - TheStreet.com
Bristol-Myers' New Nivolumab Trial Sparks Worries 10:15 a.m. Jan. 23, 2014 - Investors Business Daily
Drugmaker Merck Tries To Jump-Start Slow Growth 4:50 p.m. Jan. 22, 2014 - Investors Business Daily
5 Stocks That Dominated The Market Wednesday 3:34 p.m. Jan. 22, 2014 - 247WallSt.com
Johnson & Johnson Balances Earnings Beat With Modest Guidance 9:23 a.m. Jan. 21, 2014 - Wall St. Cheat Sheet
Buy Recommendation Reiterated For Merck & Co Inc 9:05 a.m. Jan. 21, 2014 - TheStreet.com
How Big Are Emerging Markets? 8:32 a.m. Jan. 21, 2014 - GuruFocus.com
Will 'Dogs of the Dow' ETF Continue to Shine in 2014? - ETF News And Commentary 7:45 a.m. Jan. 21, 2014 - Zacks.com
J&J Needs to Earn Investor Loyalty 1:30 p.m. Jan. 20, 2014 - WSJ.com
GCVRZ: Betting On The Sales Of Lemtrada In A Moving MS Drug Market 2:05 p.m. Jan. 19, 2014 - Seeking Alpha
Forest Laboratories - Aptalis Deal Sparks More Enthusiasm 4:20 a.m. Jan. 19, 2014 - Seeking Alpha
RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics 10:06 a.m. Jan. 24, 2014 - ACCESSWIRE
ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet 8:05 a.m. Jan. 24, 2014 - GlobeNewswire
Formex CSO Blair West to Speak at 3rd Drug Formulation & Bioavailability Conference 10:00 a.m. Jan. 23, 2014 - PR Newswire - PRF
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
John Daly, Previous Merck Exec., Offers Consulting Tips 6:35 p.m. Jan. 17, 2014 - Marketwire
Sanford Heisler Adds Four New Class Representatives To $250M Gender Discrimination Class Action Suit Against Pharma Giant Merck 10:03 a.m. Jan. 17, 2014 - PR Newswire - PRF
Trimel Announces Appointment of Tom Rossi to Its Board of Directors 5:08 p.m. Jan. 16, 2014 - Marketwire
Merck Statement on FDA Advisory Committee for Vorapaxar, Merck’s Investigational Antiplatelet Medicine 6:59 p.m. Jan. 15, 2014 - BusinessWire - BZX
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference 8:35 a.m. Jan. 13, 2014 - BusinessWire - BZX
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck 9:00 p.m. Jan. 12, 2014 - BusinessWire - BZX
Biotech Investing Strategies in 2014 Is Key Topic Bringing Investors to San Francisco for Biotech Showcase(TM) 2014 Next Week, January 13 10:59 a.m. Jan. 9, 2014 - BusinessWire
Dako to collaborate with Merck on development of companion diagnostics for cancer treatment 9:16 a.m. Jan. 9, 2014 - GlobeNewswire
Dako to collaborate with Merck on development of companion diagnostics for cancer treatment 9:00 a.m. Jan. 9, 2014 - Thomson Reuters ONE
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension 8:29 a.m. Jan. 8, 2014 - BusinessWire
Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix 8:00 a.m. Jan. 8, 2014 - PR Newswire
Forma Therapeutics Appoints Christopher Dinsmore to Vice President, Medicinal and Computational Chemistry 8:00 a.m. Jan. 7, 2014 - BusinessWire
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
Merck to Hold Fourth-Quarter 2013 Sales and Earnings Conference Call on February 5 4:59 p.m. Jan. 6, 2014 - BusinessWire
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma 7:00 a.m. Dec. 30, 2013 - Marketwire
(0)
(0)Scroll down for more posts ▼